Medical Gyeonggi e-News

[T&R Biofab] Overcoming the technological limitations of regenerative medicine

  • Name 관리자
  • Date 2022-05-24
  • Views 866

Overcoming the technological limitations of regenerative medicine with 3D bioprinting technology

 

*Photo: T&R Biofab CEO) Yun Won-soo

 

Please introduce T&R Biofab.

Technological limitations of regenerative medicine to be overcome with 3D bioprinting technology

 

- Established in 2013, our company develops, manufactures, and sells “biodegradable artificial scaffolds” using 3D bioprinting source technology, and was listed on the KOSDAQ in 2018. In order to overcome existing technological limitations of regenerative medicine with 3D bioprinting technology, we have developed materials technology, process technology, and cell technology, which are considered to be the core of 3D bioprinting, and established a full-cycle platform by ourselves. We are proud to say that we are one of the world’s leading companies in terms of 3D bioprinting patents. The regenerative medical market across the world is expected to grow to about $76.8 billion by 2024. In order to respond to global demand, we are building a GMP production plant in Siheung.

 

*Photo: T&R Mesh in various forms

 

Please briefly explain the characteristics of the “biodegradable artificial scaffold.”

Safe, effective, and convenient to use

- It is an artificial scaffold that can be implanted in the body and is made of biodegradable polymer materials using 3D printing technology. It has been approved by the Ministry of Food and Drug Safety as a grade four medical device that is inserted into the body for the purpose of reconstructing damaged human tissues and organs, allowing the functions of tissues to be restored. Since the biodegradable artificial scaffold uses biodegradable raw materials, it is slowly absorbed and decomposed and released out of the body within two to three years. It is manufactured as a customized product that is flexible and easy to apply and reduces surgery time. Compared to conventional facial contour reconstruction, reconstruction tailored to the patient’s face is possible. Safety is also ensured as it is produced with FDA-approved PCL and β-TCP.

 

*Photo: T&R Mesh whose form can be changed easily

 

How about the situation pertaining to overseas markets, and what are your future business directions and blueprints?

 Efforts to respond to global demand based on Southeast Asia and Europe

- The regenerative medical market across the world is expected to grow to about $76.8 billion by 2024. In order to respond to global demand, a GMP production plant is currently being built in Siheung, with the aim to complete the construction by the end of the year. Based on the research results obtained so far, we are accelerating commercialization. We achieved sales of about 1.2 billion won with biodegradable artificial scaffolds in 2021 and expect sales to increase in earnest this year. Currently, we are making inroads into Southeast Asian markets such as Vietnam, Thailand, and the Philippines, and European markets starting with Greece. In the future, we plan to enter the U.S. market by obtaining FDA approval.

 

HOMEPAGE: http://tnrbiofab.com/eng/main/main.html